A class action lawsuit has been filed against Erasca, Inc. (Nasdaq: ERAS), its CEO, and CFO, alleging federal securities law violations through false and misleading statements about the company's lead oncology drug candidate, ERAS-0015. The suit claims Erasca improperly compared ERAS-0015 to a competitor's drug, leading to patent and trade secret disputes, and that the truth emerged in April 2026 when the company disclosed accusations of infringement and preliminary clinical data including a patient death. Investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, have until August 10, 2026, to seek appointment as lead plaintiff.

Esab Corporation's stock has reached a new 52-week low of $83.14, marking a significant decline of 34.09% over the past year. Despite this downturn and downward revision of earnings by analysts, InvestingPro considers the stock undervalued. The company recently exceeded revenue expectations for Q1 2026, acquired Eddyfi Technologies, elected nine directors, and increased its quarterly dividend by 20%.

Fidelity National Information Services (FIS) stock has hit a 52-week low of $38.78, marking a 53% decrease from its high and reflecting broader market challenges in the financial technology sector. Despite this downturn, InvestingPro analysis suggests the stock may be undervalued based on its Fair Value assessment, offering potential upside. The company recently reported strong Q1 2026 financial results, surpassing earnings and revenue expectations, and has formed strategic alliances to enhance its service offerings.

Verizon (VZ) is presented as a solid defensive investment, despite past stock performance issues. The article notes its resiliency in a challenging telecom market and highlights its attractive 6% dividend yield as a key reason to hold the stock, with the yield not appearing to be at immediate risk. Investors are cautioned to consider potential limitations to future profitability improvements.

Datadog CEO Olivier Pomel sold 127,141 shares of Class A Common Stock for approximately $29.5 million on June 8, 2026, under a pre-arranged trading plan.

The Fabry Disease market is projected to reach approximately USD 1,700 million in 2024 and is expected to grow significantly by 2034, driven by increasing prevalence and emerging therapies. Key players like Sangamo Therapeutics are advancing gene therapies such as ST-920, with potential accelerated FDA approval. The United States holds the largest market share and diagnosed patient population, with Germany leading in Europe.

Flexsteel Industries, Inc. (NASDAQ:FLXS) has announced a 25% increase in its quarterly dividend to $0.25 per share, payable on July 6, 2026. The company has a strong dividend history, paying cash dividends for 56 consecutive years according to InvestingPro data. This follows Flexsteel exceeding third-quarter earnings expectations and executing a significant share repurchase, leading to a raised price target from Freedom Broker.

The UAW has reached a tentative agreement to end the strike at American Axle's plant in Three Rivers, Michigan. This development comes after workers had been picketing for better pay and benefits. The article was written by Kurt Nagl and published on June 10, 2026.

The United Auto Workers union has reached a tentative agreement for a new labor contract, ending a 10-day strike at a Michigan plant. This plant produces a crucial component for General Motors trucks. UAW President Shawn Fain stated that workers are "winning back a big chunk of what was taken from them" after 18 years of sacrifice.

Dot Ai (DAIC) has entered into non-binding letters of intent for a strategic preferred stock investment of up to $5 million and the sale of a portion of its operating business for up to $6 million, plus the assumption of $3 million in liabilities. These transactions aim to strengthen the company's balance sheet and ensure compliance with Nasdaq listing requirements. A potential $500,000 secured convertible note from the buyer could also provide immediate working capital, though all deals are subject to definitive agreements and various approvals.